Phase III trial results for this novel therapy are expected by the end of this year, with full regulatory filing aimed for 2028. What makes this especially important? It’s designed as an *adjunctive* therapy; meaning it works alongside existing antidepressants, offering hope to people who haven’t found relief yet. Mental health innovation in India has been slow, but global developments like this could eventually trickle down to our clinics, pharmacies, and counseling centers. It’s not a magic fix; but it’s a meaningful step. If you’ve ever felt stuck with your current meds, this one’s worth watching. Sometimes, progress doesn’t shout; it just quietly, steadily, arrives.